FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

Section obligati	this box if no long 16. Form 4 or ions may contition 1(b).		STA		ed pursu	ection 30(h) of the	a) of the	Secur	ities Exchan	ge Act of 1		SHIP	Estima	Number: ated average burd per response:	3235-0287 en 0.5		
l	nd Address of teven L.	Reporting Pers	EA	2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]							of Reporting cable) or (give title	g Person(s) to Is 10% C Other					
(Last) (First) (Middle) C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 03/22/2017							X Officer (give title Officer Scientific Officer				
(Street) WOODCLIFF LAKE NJ 07677 (City) (State) (Zip)					4. If 	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(-19)		<u> </u>		on-Deri	vative	Securities Ac	auirea	d. Di	sposed o	of. or Be	neficial	v Owned	<u> </u>				
1. Title of Security (Instr. 3) 2. Trans Date (Month/					ction	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securitie Disposed C	l (A) or	5. Amou Securiti Benefic Owned	ties cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)		(Instr. 4)		
Common	Stock			03/22	/2017		М		5,023	A	\$4.42	5,	023	D			
Common	Stock			03/22	/2017		M		2,077	A	\$12.67	7,	100	D			
Common	Stock			03/22	/2017		S		7,100	D	\$80.090	3	0	D			
Common Stock 0					/2017		M		2,025	A	\$12.67	' 2,	025	D			
Common Stock 03/23/2					/2017		M		5,000	A	\$12.63	7,	025	D			
Common Stock 03/23/2					/2017		S		7,025	D	\$82.062	.5	0	D			
			Table II			ecurities Acqualities, warrants						Owned					
1. Title of 2. 3. Transaction Barbarity Conversion Date Secution Execution			4. Transac		6. Date Exercisable and Expiration Date			7. Title and Amount of		8. Price of Derivative	Price of 9. Number of derivative		11. Nature of Indirect				

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$4.42	03/22/2017		M			5,023	(1)	04/18/2023	Common Stock	5,023	\$0.00	457	D	
Employee Stock Option (right to buy)	\$12.67	03/22/2017		М			2,077	(2)	04/07/2024	Common Stock	2,077	\$0.00	6,875	D	
Employee Stock Option (right to buy)	\$12.67	03/23/2017		М			2,025	(2)	04/07/2024	Common Stock	2,025	\$0.00	4,850	D	
Employee Stock Option (right to buy)	\$12.63	03/23/2017		М			5,000	(3)	08/25/2024	Common Stock	5,000	\$0.00	15,000	D	

Explanation of Responses:

- 1. 25% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.
- 2. 25% of the shares subject to the option vested on April 8, 2015 and the remainder shall vest in equal monthly installments over a period of three years.
- 3. 25% of the shares subject to the option vested on August 26, 2015 and the remainder shall vest in equal monthly installments over a period of three years.

Remarks:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.